Mohanakrishnan Sathyamoorthy, MD
Cardiovascular Disease · Fort Worth, TXNPI 1134233588
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Artivion, Inc. accounts for 78.5% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $8,764 and has fallen 96.8% since, to $278 in 2025. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 100 payments — averaging $291.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Artivion, Inc.$23K
- Novartis$4K
- Pfizer$262
- E.r. Squibb & Sons, L.L.C.$242
- Amarin Pharma, Inc.$221
- Amgen$182
- plus $1K from 22 others
Across 10 payments — averaging $7477.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$74K
- Artivion, Inc.$1K
What the payments were for
- Consulting fees$8,82830%
- Speaking & faculty fees$13,65847%
- Travel & lodging$3,62312%
- Food & beverage$2,96910%
- Education$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Artivion, Inc. | 23 | $22,873 |
| Novartis | 3 | $4,180 |
| Pfizer | 14 | $262 |
| E.r. Squibb & Sons, L.L.C. | 11 | $242 |
| Amarin Pharma, Inc. | 2 | $221 |
| Amgen | 6 | $182 |
| Merck | 8 | $168 |
| Sirtex Medical Inc | 1 | $112 |
| Sanofi-aventis U.S. LLC | 7 | $108 |
| Alnylam Pharmaceuticals Inc. | 1 | $104 |
| Atricure, Inc. | 1 | $87 |
| Cleerly, Inc. | 1 | $82 |
| Sanofi | 1 | $82 |
| Boston Scientific | 3 | $75 |
| Abbott | 3 | $67 |
| Novo Nordisk | 2 | $39 |
| Irhythm Technologies, Inc. | 1 | $38 |
| Boehringer Ingelheim | 2 | $38 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $26 |
| Medtronic | 1 | $23 |
| AstraZeneca | 1 | $22 |
| Baxter Healthcare | 1 | $19 |
| Biotronik Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Gilead | 1 | $16 |
| GSK | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Heartflow, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,131 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 499 | $599,269 |
| XareltoRivaroxaban | 203 | $216,586 |
| EntrestoSacubitril/Valsartan | 189 | $191,015 |
| MultaqDronedarone Hcl | 49 | $47,664 |
| VascepaIcosapent Ethyl | 71 | $46,321 |
| Repatha SureclickEvolocumab | 28 | $33,264 |
| Ranolazine ErRanolazine | 273 | $26,619 |
| JardianceEmpagliflozin | 28 | $22,833 |
| CorlanorIvabradine Hcl | 24 | $18,049 |
| Icosapent Ethyl | 35 | $17,528 |
| NexletolBempedoic Acid | 15 | $14,748 |
| Metoprolol Succinate | 862 | $10,466 |
| Nifedipine ErNifedipine | 313 | $6,706 |
| Rosuvastatin Calcium | 421 | $5,934 |
| Repatha SyringeEvolocumab | 11 | $5,801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $262 | $599,269499 claims |
| NovartisEntresto | $4,180 | $191,015189 claims |
| Sanofi-aventis U.S. LLCMultaq | $108 | $47,66449 claims |
| Boehringer IngelheimJardiance | $38 | $22,83328 claims |
| AmgenCorlanor | $182 | $18,04924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Fort Worth
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
- Reynolds DelgadoHouston$471K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.